TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26556081

Group type: EXPERIMENTAL
Intervention: Exercise group (15 minutes running at 65-75% HRmax)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Psychosocial stress group (working on a standard intelligence test under stress)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (regular class session)
Number of subjects: 57
Study: 22885913

Group type: EXPERIMENTAL
Intervention: Alcohol (0.65 g/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-alcohol condition
Number of subjects: 12
Study: 21850690

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) and corticosteroids (arm 1; n = 77)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF), TAC, and corticosteroids (arm 2; n = 72)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF), TAC, and daclizumab induction with no corticosteroids (arm 3; n = 146)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Steroid-free immunosuppression (arm 3)
Number of subjects: 295

Group type: COMPARATOR
Intervention: All arms (1, 2, and 3)
Number of subjects: 295
Study: 19644398

Group type: EXPERIMENTAL
Intervention: Olive oil-based (OL) lipid emulsion
Number of subjects: 44

Group type: COMPARATOR
Intervention: Soybean oil (SO) lipid emulsion
Number of subjects: 44
Study: 17960954

Group type: EXPERIMENTAL
Intervention: Entecavir 0.5mg/day
Number of subjects: 709

Group type: COMPARATOR
Intervention: Lamivudine 100mg/day plus adefovir 10mg/day for those with virologic breakthrough
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 709

Group type: COMPARATOR
Intervention: Combination therapy for treatment-naive patients (lamivudine plus adefovir)
Number of subjects: 709
Study: 15578509

Group type: COMPARATOR
Intervention: Conventional percutaneous ethanol injection (PEI)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Higher-dose percutaneous ethanol injection (PEI)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation
Number of subjects: 157
Study: 12575553

Group type: EXPERIMENTAL
Intervention: Yiqi Bushen Huoxue herbs (YQBSHX)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 9597406

Group type: EXPERIMENTAL
Intervention: Stable angina pectoris patients
Number of subjects: 859

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Stable angina pectoris patients (males)
Number of subjects: 859
Study: 7842985

Group type: EXPERIMENTAL
Intervention: Zhuling (Grifola umbellata pilat)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 146
Study: 2896126

Group type: EXPERIMENTAL
Intervention: Intravenous chlordesmethyldiazepam (1 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral chlordesmethyldiazepam (tablets)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral chlordesmethyldiazepam (drops)
Number of subjects: 6
Study: 29278044

Group type: EXPERIMENTAL
Intervention: additional moderate‐ to vigorous‐intensity physical activity (3 schools)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: additional light‐intensity physical activity (3 schools)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: restriction of light‐intensity physical activity and moderate‐ to vigorous‐intensity physical activity (3 schools)
Number of subjects: 156
Study: 27610935

Group type: EXPERIMENTAL
Intervention: Snus
Number of subjects: 391

Group type: COMPARATOR
Intervention: Nicotine gum
Number of subjects: 391
Study: 25541227

Group type: EXPERIMENTAL
Intervention: 2g/day of plant stanols
Number of subjects: 182

Group type: COMPARATOR
Intervention: unsupplemented yogurt (control)
Number of subjects: 182
Study: 23339348

Group type: EXPERIMENTAL
Intervention: Urbanized Himba
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional Himba
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive load imposed on traditional Himba
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Engaging stimuli/tasks
Number of subjects: 0
Study: 20486620

Group type: EXPERIMENTAL
Intervention: Homeopathic remedies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homeopathy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17996006

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 microg/kg IV before remifentanil infusion (Group Pre)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo before remifentanil infusion (Group Post)
Number of subjects: 100
Study: 15850632

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12829989

Group type: EXPERIMENTAL
Intervention: Peginterferon or interferon alfa-2b and ribavirin
Number of subjects: 1428

Group type: COMPARATOR
Intervention: Control group (other genotypes)
Number of subjects: 1428
Study: 10985648

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoniazid/Rifampicin regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoniazid (without rifampicin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampicin (or rifapentine) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher dose of rifampicin
Number of subjects: 0
Study: 8675921

Group type: EXPERIMENTAL
Intervention: Weight-bearing exercises (walking, stepping up and down from benches), aerobic dancing, and flexibility exercises for 60 minutes, three times a week, over a period of 12 months
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 124
Study: 1511814

Group type: COMPARATOR
Intervention: Immediate injection sclerotherapy (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sclerotherapy preceded by balloon tamponade (group B)
Number of subjects: 60
Study: 6396365

Group type: EXPERIMENTAL
Intervention: Streptokinase 1.5 X 10(6) units/90 minutes
Number of subjects: 33

Group type: COMPARATOR
Intervention: Routine continuous i.v. heparin treatment (1000 units/h)
Number of subjects: 33
Study: 31427346

Group type: EXPERIMENTAL
Intervention: Interpersonal counselling (IPC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 60
Study: 30020205

Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Remediation (CR) training
Number of subjects: 20
Study: 26825278

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) applied to quadriceps muscles bilaterally from the first postoperative day until ICU discharge for a maximum of 14 days.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group with electrodes applied but no electricity delivered.
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 54
Study: 24657991

Group type: EXPERIMENTAL
Intervention: Intervention Condition (IC): Patient education, home BP monitoring, monthly lifestyle counseling, and physicians attending monthly hypertension case rounds with feedback on home BP readings.
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Usual Care (UC): Printed patient education material and hypertension treatment guidelines for physicians.
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Intervention Condition (IC) in patients without diabetes mellitus: Patient education, home BP monitoring, monthly lifestyle counseling, and physicians attending monthly hypertension case rounds with feedback on home BP readings.
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Usual Care (UC) in patients without diabetes mellitus: Printed patient education material and hypertension treatment guidelines for physicians.
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Intervention Condition (IC) in small-sized community health centers: Patient education, home BP monitoring, monthly lifestyle counseling, and physicians attending monthly hypertension case rounds with feedback on home BP readings.
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Usual Care (UC) in small-sized community health centers: Printed patient education material and hypertension treatment guidelines for physicians.
Number of subjects: 1059
Study: 22018821

Group type: EXPERIMENTAL
Intervention: Nasoalveolar moulding (NAM) within 1 month of age
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nasoalveolar moulding (NAM) between 1 and 5 months of age
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (non‐cleft 18‐month old children)
Number of subjects: 15
Study: 20015855

Group type: EXPERIMENTAL
Intervention: Choice Stepping Reaction Time (CSRT) test
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: CSRT performance
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Physiological parameters (reaction time and balance performance)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Quadriceps strength and visual contrast sensitivity
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Cognitive processing
Number of subjects: 294
Study: 17686184

Group type: EXPERIMENTAL
Intervention: 12-week supervised aerobic exercise program (ImPACT Program)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 40
Study: 15543117

Group type: EXPERIMENTAL
Intervention: A combination of inhaled medical air and titrated intravenous midazolam
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: A combination of inhaled 40% nitrous oxide in oxygen and titrated intravenous midazolam
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: A combination of an inhaled mixture of 0.3% sevoflurane and 40% nitrous oxide in oxygen with titrated intravenous midazolam
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 65
Study: 11463590

Group type: EXPERIMENTAL
Intervention: Inhibition of deep inspiration during methacholine inhalation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Allowed deep inspiration during methacholine inhalation
Number of subjects: 8
Study: 9529467

Group type: EXPERIMENTAL
Intervention: Oral sucrose
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB)
Number of subjects: 119

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 119
Study: 7994787

Group type: EXPERIMENTAL
Intervention: 30 mg FARM by intravesical instillation every 2-4 weeks for 1 year
Number of subjects: 73

Group type: COMPARATOR
Intervention: 30 mg ADR by intravesical instillation every 2-4 weeks for 1 year
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 30 mg FARM
Number of subjects: 73

Group type: COMPARATOR
Intervention: 30 mg ADR
Number of subjects: 73
Study: 2521868

Group type: EXPERIMENTAL
Intervention: Cimetidine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 0
Study: 173124

Group type: EXPERIMENTAL
Intervention: Natural ACTH
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Synthetic ACTH
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Natural and Synthetic ACTH
Number of subjects: 20
Study: 31797399

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis BB-12® (1 × 10^9 CFU/day)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis BB-12®
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 31455897

Group type: EXPERIMENTAL
Intervention: Optimizing energy and protein intake
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Weight gain (1 kilo increase)
Number of subjects: 117
Study: 29284715

Group type: EXPERIMENTAL
Intervention: Group A: risk assessment using a validated tool (AUSDRISK)
Number of subjects: 10304

Group type: EXPERIMENTAL
Intervention: Group B: AUSDRISK assessment followed by point‐of‐care glycated haemoglobin testing
Number of subjects: 10304

Group type: EXPERIMENTAL
Intervention: Group C: AUSDRISK assessment followed by point‐of‐care blood glucose testing
Number of subjects: 10304

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 10304

Group type: EXPERIMENTAL
Intervention: Economic outcome measure
Number of subjects: 10304
Study: 25679122

Group type: EXPERIMENTAL
Intervention: Citalopram plus naltrexone and clinical case management
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo plus naltrexone and clinical case management
Number of subjects: 138
Study: 25916132

Group type: EXPERIMENTAL
Intervention: Intravenous laser therapy (ILIB‐405) along with traditional drug treatment (proton pump inhibitors, antacids, prokinetics) in the main group (70 patients).
Number of subjects: 102

Group type: COMPARATOR
Intervention: Traditional drug treatment (control group, 30 patients).
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intravenous laser therapy (ILIB‐405) along with traditional drug treatment in the main group (70 patients).
Number of subjects: 102
Study: 21975041

Group type: EXPERIMENTAL
Intervention: Epilation
Number of subjects: 2556

Group type: EXPERIMENTAL
Intervention: Epilation in patients with severe entropion
Number of subjects: 2556
Study: 19207889

Group type: EXPERIMENTAL
Intervention: Ultrasonic debridement (UD)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) with hand instruments
Number of subjects: 33
Study: 17401693

Group type: COMPARATOR
Intervention: Phosphate supplement
Number of subjects: 16

Group type: COMPARATOR
Intervention: Meat
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cheese
Number of subjects: 16
Study: 15321804

Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg), vitamin B‐12 (0.4 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vitamin B‐6 (40 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg) and vitamin B‐12 (0.4 mg) with additional folic acid (5 mg/d) for the first 2 weeks
Number of subjects: 90
Study: 11254913

Group type: EXPERIMENTAL
Intervention: Combination hormone replacement therapy (17beta-estradiol plus medroxyprogesterone acetate)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Estrogen replacement therapy (ERT) alone (either 17beta-estradiol (1 mg) or conjugated equine estrogens (CEE) (0.625 mg))
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 9677811

Group type: EXPERIMENTAL
Intervention: Plant product based on extracts of Salvia officinalis (sage) and Medicago sativa (alfalfa)
Number of subjects: 30
Study: 7793393

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 2606

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2606

Group type: COMPARATOR
Intervention: Patients with wall motion index > 1.2
Number of subjects: 2606
Study: 2196149

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally twice daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Cefaclor 250 mg over 8 hr for 5 days or longer
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 55
Study: 160237

Group type: EXPERIMENTAL
Intervention: Diazepam 0.16 mg kg‐1
Number of subjects: 0
Study: 30764646

Group type: EXPERIMENTAL
Intervention: Group Stepping Stones Triple P (GSSTP)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Waiting List Control (WLC)
Number of subjects: 84
Study: 28109939

Group type: COMPARATOR
Intervention: Instructor-led teaching
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Peer-assisted learning
Number of subjects: 86
Study: 25492571

Group type: COMPARATOR
Intervention: Remifentanil target concentration 0 ng/ml
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Remifentanil target concentration 1 ng/ml
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Remifentanil target concentration 2 ng/ml
Number of subjects: 75
Study: 24476018

Group type: EXPERIMENTAL
Intervention: Group Swab-Scrub
Number of subjects: 192

Group type: COMPARATOR
Intervention: Group Control
Number of subjects: 192
Study: 22896735

Group type: EXPERIMENTAL
Intervention: Multimin 90 (MM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study: 19602786

Group type: EXPERIMENTAL
Intervention: EE/CA plus metformin (1,700 mg, cyproterone acetate 2 mg, ethinylestradiol 35 microg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: EE/CA (cyproterone acetate 2 mg, ethinylestradiol 35 microg)
Number of subjects: 40
Study: 17868239

Group type: EXPERIMENTAL
Intervention: Health promotion nurse intervention
Number of subjects: 281
Study: 14678372

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Solifenacin 20 mg
Number of subjects: 265

Group type: COMPARATOR
Intervention: Tolterodine 2 mg
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg and 10 mg
Number of subjects: 265

Group type: COMPARATOR
Intervention: Tolterodine
Number of subjects: 265
Study: 11743286

Group type: EXPERIMENTAL
Intervention: 3 months of leuprolide plus flutamide before radical prostatectomy
Number of subjects: 282

Group type: COMPARATOR
Intervention: Prostatectomy only
Number of subjects: 282
Study: 9825973

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.25 mg kg(‐1) b.i.d. on d 1‐7; 0.12 mg kg(‐1) b.i.d. on d 8‐14; 0.05 mg kg(‐1) b.i.d. on d 15‐21; 0.02 mg kg(‐1) b.i.d. on d 22‐28)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 7663802

Group type: EXPERIMENTAL
Intervention: 5-lipoxygenase inhibitor (zileuton)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2667313

Group type: EXPERIMENTAL
Intervention: Alternating-calorie diet with exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Constant-calorie diet with exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternating-calorie diet without exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Constant-calorie diet without exercise
Number of subjects: 0
Study: 656270

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid 750 mg daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clofibrate 2 g daily
Number of subjects: 10
Study: 30592235

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser plus NB-UVB
Number of subjects: 30

Group type: COMPARATOR
Intervention: NB-UVB alone
Number of subjects: 30
Study: 27838276

Group type: EXPERIMENTAL
Intervention: Cerebellar anodal tDCS (5 days/week for 2 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 26033312

Group type: COMPARATOR
Intervention: Bupivacaine 2 mg·kg(‐1) (0.8 ml·kg(‐1))
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Bupivacaine 2 mg·kg(‐1) + dexmedetomidine 1 μg·kg(‐1)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Bupivacaine 2 mg·kg(‐1) + dexmedetomidine 2 μg·kg(‐1)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Bupivacaine 2 mg·kg(‐1)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Bupivacaine 2 mg·kg(‐1) + dexmedetomidine 1 μg·kg(‐1) and 2 μg·kg(‐1)
Number of subjects: 91
Study: 23868620

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid (UDCA) 300-450 mg/d
Number of subjects: 87

Group type: COMPARATOR
Intervention: Diet (1200 Kcal/d for females, 1500 Kcal/d for males)
Number of subjects: 87
Study: 21810646

Group type: EXPERIMENTAL
Intervention: Cigarette withdrawal (heavy smoking)
Number of subjects: 48
Study: 20469779

Group type: EXPERIMENTAL
Intervention: R + G; basal‐bolus regular and glargine insulin (R‐R‐R‐G)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Premix 30/70 and R + NPH regimens
Number of subjects: 172
Study: 16955801

Group type: EXPERIMENTAL
Intervention: Freshly reconstituted rhTSH (91.5 microg IV)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Reconstituted and stored rhTSH at 4 degrees C for 4 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Reconstituted and frozen rhTSH at -20 degrees C for 8 weeks
Number of subjects: 12
Study: 17141640

Group type: EXPERIMENTAL
Intervention: Action Research Arm Test (ARAT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ARAT scores
Number of subjects: 50
Study: 12595976

Group type: EXPERIMENTAL
Intervention: Two-chamber drainage system (TCDS)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Complex closed drainage system (CCDS)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: TCDS
Number of subjects: 311

Group type: COMPARATOR
Intervention: CCDS
Number of subjects: 311
Study: 10368943

Group type: EXPERIMENTAL
Intervention: Regular sentences
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized words (nouns)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized words (prepositions)
Number of subjects: 0
Study: 8901660

Group type: EXPERIMENTAL
Intervention: 100 mg/d aspirin
Number of subjects: 409

Group type: COMPARATOR
Intervention: 650 mg/d aspirin
Number of subjects: 409
Study: 2057272

Group type: EXPERIMENTAL
Intervention: Physician counseling and take-home pamphlets
Number of subjects: 334

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Follow-up phone counseling (additional counseling)
Number of subjects: 334
Study: 6190548

Group type: EXPERIMENTAL
Intervention: Combination of high-dose cis-platinum, Oncovin (vincristine) and bleomycin (COB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly methotrexate (MTX)
Number of subjects: 0
Study: 29996127

Group type: EXPERIMENTAL
Intervention: Shortened T50 (minutes)
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Reduced fetuin‐A concentrations (g/L)
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Elevated high sensitivity c-reactive protein (hsCRP)
Number of subjects: 685
Study: 28807912

Group type: EXPERIMENTAL
Intervention: MHAA4549A (3,600 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oseltamivir (standard oral dose)
Number of subjects: 100
Study: 26611872

Group type: EXPERIMENTAL
Intervention: Concurrent exercise training
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 32
Study: 23730881

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0